Lisinopril Dose Titration and Monitoring

Introduction to Lisinopril Titration

The European Society of Cardiology recommends waiting 2-4 weeks before increasing lisinopril to 10 mg, with renal function and electrolytes checked at 1-2 weeks after initiation and again 1 and 4 weeks after any dose increase 1
Consider dose up-titration after 2-4 weeks of starting lisinopril at the initial dose, with more rapid dose up-titration possible in hospitalized patients or those closely supervised 1, 2

Check renal function and serum electrolytes within 1-2 weeks of starting treatment, and re-check at 1 and 4 weeks after increasing the dose 1, 2
Do not increase the dose if there is significant worsening of renal function or hyperkalemia 1

The European Heart Society recommends a starting dose of 2.5-5.0 mg once daily and a target dose of 20-35 mg once daily 1, 2
The ATLAS trial demonstrated a 15% relative risk reduction in death or heart failure hospitalization with high-dose lisinopril compared to low-dose lisinopril, supporting the importance of titrating to target doses 1, 2

An increase in creatinine up to 50% from baseline or to a certain level is acceptable, but if creatinine rises above a certain level, halve the dose of lisinopril, and if it exceeds a higher level, discontinue the medication 1
Significant worsening of renal function, development of hyperkalemia, and symptomatic hypotension are contraindications to dose increase 1

Renal function, potassium, blood pressure, and heart rate should be monitored with each dose adjustment 1, 3
Failure to check renal function and electrolytes before dose increases can lead to undetected hyperkalemia or renal deterioration 1
In the absence of adverse effects, aim for the evidence-based target dose rather than remaining at lower doses 1

The American College of Cardiology recommends assessing blood tests for electrolytes and renal function 2 to 4 weeks after starting lisinopril therapy, with a Class I recommendation from the 2017 ACC/AHA Hypertension Guidelines, applying to all patients starting ACE inhibitors 4, 5, 6, 7

Serum creatinine and estimated GFR should be monitored to detect renal dysfunction, as recommended by the American Journal of Kidney Diseases and the Journal of the American College of Cardiology 8, 7
Serum potassium should be monitored to identify hyperkalemia, with recommendations from Circulation, American Journal of Kidney Diseases, and the Journal of the American College of Cardiology 4, 8, 7

The American Journal of Kidney Diseases recommends checking electrolytes and renal function at 1 and 4 weeks after each dose increase, and every 3 to 6 months after achieving target dose 8

The Journal of the American College of Cardiology recommends more frequent monitoring in patients with pre-existing hypotension, hyponatremia, diabetes mellitus, azotemia, or baseline renal impairment, and those taking potassium supplements 9
The British Journal of Pharmacology recommends checking labs at 1 week, then at 1, 2, 3, and 6 months, then every 6 months if stable, in heart failure patients on aldosterone antagonists plus ACE inhibitors 10

The American Journal of Kidney Diseases recommends patient education to hold or reduce lisinopril doses during volume depletion, decreased oral intake, or aggressive diuretic therapy 8
The Journal of the American College of Cardiology recommends caution with concomitant diuretic use, which reduces hyperkalemia risk by approximately 60% 9